{{Short description|Chemical compound}} {{Use American English|date=October 2023}} {{Use dmy dates|date=October 2023}} {{cs1 config |name-list-style=vanc |display-authors=6}} {{Drugbox | image = Gefapixant structure.svg | image_class = skin-invert-image
<!--Clinical data--> | tradename = Lyfnua | ATC_prefix = R05 | ATC_suffix = DB29
| legal_US = | legal_EU = Rx-only | legal_EU_comment = <ref name="Lyfnua EPAR">{{cite web | title=Lyfnua EPAR | website=European Medicines Agency | date=29 September 2023 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lyfnua | access-date=5 October 2023}}</ref> | legal_status =
<!--Pharmacokinetic data--> | bioavailability = | metabolism = | elimination_half-life = | excretion =
<!--Identifiers--> | CAS_number = 1015787-98-0 | PubChem = 24764487 | UNII = 6K6L7E3F1L | ChemSpiderID = 58828660 | DrugBank = DB15097 | KEGG = D11349 | ChEMBL = 3716057 | synonyms = MK-7264
<!--Chemical data--> | IUPAC_name = 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide | C=14 | H=19 | N=5 | O=4 | S=1 | SMILES = CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC | StdInChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19) | StdInChIKey = HLWURFKMDLAKOD-UHFFFAOYSA-N }}
'''Gefapixant''', sold under the brand name '''Lyfnua''', is a medication used to treat chronic (long-term) cough.<ref name="Lyfnua EPAR" /> It acts as an antagonist of the P2RX3 receptor.<ref name="pmid30880151">{{cite journal | vauthors = Muccino D, Green S | title = Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough | journal = Pulmonary Pharmacology & Therapeutics | volume = 56 | pages = 75–78 | date = June 2019 | pmid = 30880151 | doi = 10.1016/j.pupt.2019.03.006 | s2cid = 81982653 | doi-access = free }}</ref><ref name="pmid30927255">{{cite journal | vauthors = Richards D, Gever JR, Ford AP, Fountain SJ | title = Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation | journal = British Journal of Pharmacology | volume = 176 | issue = 13 | pages = 2279–2291 | date = July 2019 | pmid = 30927255 | doi = 10.1111/bph.14677 | pmc = 6555852 }}</ref><ref name="pmid31726893">{{cite journal | vauthors = Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C | title = Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications | journal = Expert Opinion on Therapeutic Patents | volume = 29 | issue = 12 | pages = 943–963 | date = December 2019 | pmid = 31726893 | doi = 10.1080/13543776.2019.1693542 | s2cid = 208037373 | hdl = 11581/435751 | hdl-access = free }}</ref>
It was authorized for medical use in the European Union in September 2023.<ref name="Lyfnua EPAR" />
== Medical uses == Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.<ref name="Lyfnua EPAR" />
== Society and culture == === Names === It was named in honour of Geoff Burnstock.<ref>{{cite journal | vauthors = Ford AP, Dillon MP, Kitt MM, Gever JR | title = The discovery and development of gefapixant | journal = Autonomic Neuroscience | volume = 235 | article-number = 102859 | date = November 2021 | pmid = 34403981 | doi = 10.1016/j.autneu.2021.102859 | s2cid = 236524967 }}</ref>
== References == {{Reflist}}
{{Cough and cold preparations}} {{Portal bar | Medicine}} {{Authority control}}
Category:Benzosulfones Category:Diaryl ethers Category:Drugs developed by Merck & Co. Category:Sulfonamides
{{respiratory-system-drug-stub}}